Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data?
TheFly reported on July 7 that Oppenheimer reaffirmed its Outperform rating and $20 price target on CMPS shares following new Phase 3 COMP006 26-week results.







